Chromones: Privileged scaffold in anticancer drug discovery

• Published in: Chemical biology & drug design 2021-11, Vol.98 (5), p.943-953
• Main Authors: Patil, Vaishali M., Masand, Neeraj, Verma, Saroj, Masand, Vijay
• Format: Article
• Language: English
• Subjects: anticancer agents; Antineoplastic Agents - chemistry; Antineoplastic Agents - pharmacology; chromones; Chromones - chemistry; Chromones - pharmacology; Drug Design; Drug Screening Assays, Antitumor; fused and simple chromone; Humans; natural products; Neoplasms - drug therapy; privileged scaffolds; Protein Kinase Inhibitors - chemistry; Protein Kinase Inhibitors - pharmacology; Structure-Activity Relationship; synthetic chromone
• ISSN: 1747-0277; 1747-0285
• DOI: 10.1111/cbdd.13951

In the design and discovery of anticancer drugs, various natural heterocyclic scaffolds have attracted considerable interest as privileged structures. For rational drug design, some of the natural scaffolds such as chromones have exhibited wide acceptability due to their drug‐like properties. Among the approved anticancer drugs, the scaffolds with high selectivity for a small group of closely related targets are of importance. In the development of selective anticancer agents, the natural, as well as synthetic, can generate highly selective compounds toward cancer targets. The present manuscript includes more particularly the development of cancer inhibitors incorporating the chromone scaffold, with a strong emphasis on their molecular interactions in the anticancer mechanism. It also includes the structure‐activity relationship studies and related examples of lead optimization. In the design and discovery of anticancer drugs, various natural heterocyclic scaffolds have attracted considerable interest as privileged structures. In the development of selective anticancer agents, the natural, as well as synthetic chromones, can be utilized to generate highly selective compounds towards cancer targets.